Evidence mapPaperPMID 33573121Full record

ReviewMolecules (Basel, Switzerland)2021

Clinical Efficacy of Brown Seaweeds

Enver Keleszade, Michael Patterson, Steven Trangmar, Kieran J Guinan, Adele Costabile

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Role ofMarine drugs · 2025
    Article
  3. Review
  4. Review
  5. Green (Journal of immunology research · 2024
    Article
  6. Article
  7. Awareness about Patterson syndrome among dental students.Journal of advanced pharmaceutical technology & research · 2022
    Article
  8. Article
  9. Article
  10. Brown SeaweedNutrients · 2021
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Enver KeleszadeDepartment of Life Sciences, University of Roehampton, London SW15 4JD, UK.ORCID 0000-0002-8779-0863
Michael PattersonDepartment of Life Sciences, University of Roehampton, London SW15 4JD, UK.
Steven TrangmarDepartment of Life Sciences, University of Roehampton, London SW15 4JD, UK.ORCID 0000-0002-1928-4328
Kieran J GuinanBioAtlantis Ltd., Tralee, V92 RWV5 Co. Kerry, Ireland.ORCID 0000-0003-0887-0927
Adele CostabileDepartment of Life Sciences, University of Roehampton, London SW15 4JD, UK.ORCID 0000-0003-3185-030X

Funding

BioAtlantis Ltd. (Ireland) Russel PhD Studentship Agreement (Ref. LSC 2018_66).
6 · The paper itself

Abstract

Metabolic syndrome (MetS) is a global public health problem affecting nearly 25.9% of the world population characterised by a cluster of disorders dominated by abdominal obesity, high blood pressure, high fasting plasma glucose, hypertriacylglycerolaemia and low HDL-cholesterol. In recent years, marine organisms, especially seaweeds, have been highlighted as potential natural sources of bioactive compounds and useful metabolites, with many biological and physiological activities to be used in functional foods or in human nutraceuticals for the management of MetS and related disorders. Of the three groups of seaweeds, brown seaweeds are known to contain more bioactive components than either red and green seaweeds. Among the different brown seaweed species,

Indexed as

AscophyllumClinical Trials as TopicFucusGlycoside Hydrolase InhibitorsHumansMetabolic SyndromePlant ExtractsSeaweedGlycoside Hydrolase InhibitorsPlant ExtractsAscophyllum nodosumFucus vesiculosusmetabolic syndromeseaweeds

Identifiers

PMID33573121
PMCPMC7866543

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.